Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
OMNI logo — Pioneering advanced respiratory drug delivery solutions for...

OMNI

Pioneering advanced respiratory drug delivery solutions for asthma and chronic obstructive pulmonary disease.

Founded 2011 Series D Total: $33.00M Biotechnology, Health Care +2

General Information

Company Name OMNI
Founded Year 2011
Industries Biotechnology, Health Care, Medical Devices +1
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with OMNI. To contact OMNI, visit omni-pharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does OMNI compare?

A PDF of OMNI and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting OMNI soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About OMNI

OMNI is a cutting-edge pharmaceutical company dedicated to advancing drug delivery technology, particularly in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease. The company specializes in a range of inhalation dosage forms, including inhalation aerosols, inhalation powder aerosols, nebulized solutions, and nasal sprays. In addition, OMNI provides a design platform to support respiratory devices for these conditions. Since its founding in 2011, the company has attracted significant attention from investors, culminating in a Series D investment on 27 December 2021. This round of funding was backed by a consortium of prominent investors, including Shanghai Healthcare Capital, Bank of China Group Investment Limited, Taikun Capital, Zhongxin Capital, Zhangkelingyi, and KPCB China. With its focus on pioneering advanced respiratory drug delivery solutions, OMNI is poised to make a significant impact in the Biotechnology, Health Care, Medical Devices, and Pharmaceutical industries.

Business keywords: respiratory drug delivery, asthma treatment, COPD treatment, pharmaceutical company, drug delivery technology, inhalation dosage forms, inhalation aerosols, inhalation nebulized solutions, nasal sprays, respiratory devices, innovative technology, pharmaceutical innovation, biopharmaceutical, respiratory health, pharmaceutical design platform

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Series D Undisclosed 6
Shanghai Healthcare Capital Bank of China Group Investment Limited Taikun Capital
Shanghai Healthcare Capital, Bank of China Group Investment Limited +4
27 Dec 2021
Series D Undisclosed 1
Vivo Capital
Vivo Capital
10 Mar 2021
Series C Undisclosed 1
BioVenture
01 Dec 2020
Series C Undisclosed 2
Vivo Capital SDIC Ventures
Vivo Capital, SDIC Ventures
17 Nov 2017
Series B CNY20.00M 3
SDIC Ventures
SDIC Ventures, Vivo Olive Surplus HK VIII Limited +1
29 Sep 2017
Series A CNY10.00M 2
Shanghai Liyi Investment Management, Shanghai Chenshan Investment Management
22 Sep 2015
Angel Round CNY3.00M -
19 Feb 2013

OMNI Alternatives & Competitors

OMNI vs
Resproly
Resproly

Pioneering advanced respiratory solutions for Asthma, COPD, Diabetes, and Parkinson's Disease.

Series B
Biopharma, Biotechnology
OMNI vs
Softhale
Softhale

Advancing the future of lung drug delivery with innovative Soft Mist Inhalation devices

Series A
Biotechnology, Health Care
OMNI vs
Drogsan Pharmaceuticals
Drogsan Pharmaceuticals Turkey

Respect to Health

483 employees
Biotechnology, Manufacturing

FAQ About OMNI

Pioneering advanced respiratory drug delivery solutions for asthma and chronic obstructive pulmonary disease.
OMNI was founded in 2011.
OMNI operates in Biotechnology, Health Care, Medical Devices and Pharmaceutical. Its work centres on respiratory drug delivery, asthma treatment, COPD treatment and pharmaceutical company.
OMNI has completed 7 funding rounds, raising a total of $33.00M. The latest funding stage is Series D.
Top alternatives and competitors to OMNI include Resproly, Softhale, Drogsan Pharmaceuticals, Chance Pharmaceuticals 畅溪制药, LTS Lohmann Therapie-Systeme AG. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OMNI and Resproly are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OMNI, https://bouncewatch.com/company/omni-2, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes